COVID-19 and the liver: What do we know so far?

Nasa, Prashant; Alexander, G.

doi:10.4254/wjh.v13.i5.522

Cited by 18 publications

(28 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…General measures for all patients, such as physical distancing, staying away from closed spaces without a face mask, handwashing, and correct education on infection preventive measures, may be enough for preventing the infection in CLD and HCC patients [ 2 , 17 ]. Measures required largely differ across regions and individual institutions, according to the level of effort imposed by the pandemic (for example, the availability of resources such as personal protective equipment and inpatient beds as well as the number of inpatients infected with SARS-CoV-2) [ 17 ].…”

Section: Measures To Reduce the Risk Of Covid-19 In Hcc Patientsmentioning

confidence: 99%

Impact of SARS-CoV-2 Pandemic on the Management of Patients with Hepatocellular Carcinoma

Guarino

Cossiga

Capasso

et al. 2022

JCM

View full text Add to dashboard Cite

Worldwide, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) significantly increases mortality and morbidity. The Coronavirus Disease 2019 (COVID-19) outbreak has had a considerable impact on healthcare systems all around the world, having a significant effect on planned patient activity and established care pathways, in order to meet the difficult task of the global pandemic. Patients with hepatocellular carcinoma (HCC) are considered a particularly susceptible population and conceivably at increased risk for severe COVID-19 because of two combined risk factors: chronic advanced liver disease and HCC itself. In these challenging times, it is mandatory to reshape clinical practice in a prompt way to preserve the highest standards of patient care and safety. However, due to the stay-at-home measures instituted to stop the spread of COVID-19, HCC surveillance has incurred a dramatic drop, and care for HCC patients has been rearranged by refining the algorithm for HCC treatment to the COVID-19 pandemic, permitting these patients to be safely managed by identifying those most at risk of neoplastic disease progression.

show abstract

Section: Measures To Reduce the Risk Of Covid-19 In Hcc Patientsmentioning

confidence: 99%

Impact of SARS-CoV-2 Pandemic on the Management of Patients with Hepatocellular Carcinoma

Guarino

Cossiga

Capasso

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“…of COVID-19 patients (Cai et al, 2020;Metawea et al, 2021;Nasa and Alexander, 2021;Yousif, 2021). However, little is known about the histopathological features of the liver during infection.…”

Section: Introductionmentioning

confidence: 99%

Potential histopathological and immunological effects of SARS-CoV-2 on the liver

Alnamshan

2022

Braz. J. Biol.

View full text Add to dashboard Cite

The coronavirus disease outbreak of 2019 (COVID-19) poses a serious threat to public health worldwide. Lung injury is the most common complication of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection. However, other organs, including the liver, can also be affected. Currently, there is limited evidence that liver impairment is associated with severe SARS-CoV-2 infection. Clinicians will need to determine whether liver injury is caused by an underlying liver condition, COVID-19 therapy, the virus directly, or immune-mediated inflammation or represents a complicated disease course in the context of COVID-19. To address the scarcity of data on histopathological changes and immunological effects on the liver with COVID-19 positivity, we analyze and summarize recent findings. We searched PubMed, Medline, Google Scholar, Science Direct, Scopus, and Web of Science databases up to December 1, 2021, identifying published studies with the search terms “Histopathology in COVID-19,” “COVID-19,” “Pathological changes in liver in COVID-19,” “Liver pathology in COVID-19,” “immunological effects in liver in COVID-19,” and “SARS-CoV-2.” This concise review will aid clinicians and researchers in better understanding the tissue histopathology and immunological consequences of SARS-CoV-2 on the liver, enabling improved care planning and avoiding future dangers.

show abstract

“…By September 2, 2022, the disease had resulted in 601189435 infections and 6475346 deaths[ 1 ]. In addition to respiratory symptoms and fever, 14%-69% of patients with COVID-19 have abnormal liver function tests, mainly manifested by elevations of hypoalbuminemia, gamma-glutamyl transferase, alanine aminotransferase (ALT) and aspartate aminotransferase (AST)[ 2 , 3 ]. Patients with severe diseases are more likely to develop elevated liver tests, suggesting an association between liver injury and the severity of disease[ 2 , 4 ].…”

Section: Introductionmentioning

confidence: 99%

“…In addition to respiratory symptoms and fever, 14%-69% of patients with COVID-19 have abnormal liver function tests, mainly manifested by elevations of hypoalbuminemia, gamma-glutamyl transferase, alanine aminotransferase (ALT) and aspartate aminotransferase (AST)[ 2 , 3 ]. Patients with severe diseases are more likely to develop elevated liver tests, suggesting an association between liver injury and the severity of disease[ 2 , 4 ]. Possible mechanisms of COVID-19-related liver injury include direct SARS-CoV-2-induced cytopathic injury to hepatocytes and cholangiocytes, immune dysregulation and hypoxic liver injury, and drug-induced liver injury[ 5 ].…”

Section: Introductionmentioning

confidence: 99%

Liver test abnormalities in asymptomatic and mild COVID-19 patients and their association with viral shedding time

Yu¹,

Xie²,

Luo³

et al. 2022

World J Hepatol

View full text Add to dashboard Cite

BACKGROUND Asymptomatic infections and mild symptoms are common in patients infected with the Omicron variant, and data on liver test abnormalities are rare. AIM To evaluated the clinical characteristics of asymptomatic and mild coronavirus disease 2019 (COVID-19) patients with abnormal liver test results. METHODS This retrospective study included 661 laboratory-confirmed asymptomatic and mild COVID-19 patients who were treated in two makeshift hospitals in Ningbo from April 5, 2022 to April 29, 2022. Clinical information and viral shedding time were collected, and univariate and multivariate logistic regression models were performed in statistical analyses. RESULTS Of the 661 patients, 83 (12.6%) had liver test abnormalities, and 6 (0.9%) had liver injuries. Abnormal liver tests revealed a reliable correlation with a history of liver disease ( P < 0.001) and a potential correlation with male sex and obesity ( P < 0.05). Elevated alanine aminotransferase was reliably associated with obesity ( P < 0.05) and a history of liver disease ( P < 0.001). Elevated aspartate transaminase (AST) was reliably correlated with a history of liver disease ( P < 0.001), and potentially correlated with age over 30 years ( P < 0.05). There was a reliable correlation between AST ≥ 2× the upper limit of normal and a longer viral shedding time, especially in mild cases. CONCLUSION Obesity and a history of liver disease are risk factors for liver test abnormalities. Being male and an older age are potential risk factors. Attention should be given to liver tests in asymptomatic and mild COVID-19 patients, which has crucial clinical significance for evaluating the viral shedding time.

show abstract

COVID-19 and the liver: What do we know so far?

Cited by 18 publications

References 56 publications

Impact of SARS-CoV-2 Pandemic on the Management of Patients with Hepatocellular Carcinoma

Impact of SARS-CoV-2 Pandemic on the Management of Patients with Hepatocellular Carcinoma

Potential histopathological and immunological effects of SARS-CoV-2 on the liver

Liver test abnormalities in asymptomatic and mild COVID-19 patients and their association with viral shedding time

Contact Info

Product

Resources

About